 |
|
|
| |
Short-term therapy with GSK3228836 in chronic hepatitis B (CHB) patients results in reductions in HBcrAg and HBV RNA: Phase 2a, randomized, double-blind, placebo-controlled study
|
| |
| |
AASLD 2020 Nov 11-16
Reported by Jules Levin
Shihyun You1, Phillip Yates2, Rob Elston2, Yu Tao1,
13 Melanie Paff , Dickens Theodore
1GSK, Collegeville, PA, USA; 2GSK, Stevenage, Hertfordshire, UK; 3GSK, Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
